Trials / Conditions / Metastatic Cholangiocarcinoma

Metastatic Cholangiocarcinoma

11 registered clinical trials studyying Metastatic Cholangiocarcinoma — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Terminated	NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma NCT06420349	Mayo Clinic	Phase 1
Active Not Recruiting	Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangio NCT06178588	University of Kansas Medical Center	Phase 2
Recruiting	Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alteratio NCT06160752	Tyra Biosciences, Inc	Phase 1
Terminated	Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Chola NCT04088188	Academic and Community Cancer Research United	Phase 1
Active Not Recruiting	Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Me NCT04068194	National Cancer Institute (NCI)	Phase 1 / Phase 2
Active Not Recruiting	Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver NCT04175912	National Cancer Institute (NCI)	Phase 2
Terminated	CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors NCT02757391	M.D. Anderson Cancer Center	Phase 1
Terminated	A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic C NCT03656536	Incyte Corporation	Phase 3
Completed	Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be NCT03201458	National Cancer Institute (NCI)	Phase 2
Completed	A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable NCT03250273	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 2
Completed	Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) NCT02989857	Institut de Recherches Internationales Servier	Phase 3